SYED M MOHIUDDIN, M.D.
Osteopathic Medicine at Webster St, Omaha, NE
License number
Nebraska 12364
Category
Osteopathic Medicine
Type
Cardiovascular Disease
Address
Address
3006 Webster St, Omaha, NE 68131
Phone
(402) 280-4566
Personal information
See more information about SYED M MOHIUDDIN at radaris.comName
Address
Phone
12531 Shamrock Rd, Omaha, NE 68154
3006 Webster St, Omaha, NE 68131
Organization information
See more information about SYED M MOHIUDDIN at bizstanding.comAlegent Creighton Cardiac Clinic - Syed M Mohiuddin MD
3006 Webster St, Omaha, NE 68131
Categories:
Cardiology Physicians & Surgeons, Physicians & Surgeons
Phone:
(402) 280-4566 (Phone)
Professional information
See more information about SYED M MOHIUDDIN at trustoria.com
Syed M Mohiuddin, Omaha NE
Syed M Mohiuddin, Omaha NE
Specialties:
Cardiologist
Address:
3006 Webster St, Omaha, NE 68131
Education:
Laval University - Doctor of Science
Osmania Medical College - Doctor of Medicine
Osmania Medical College - Doctor of Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Cardiovascular Disease (Internal Medicine)
Novel Method Of Myocardial Imaging
Novel Method Of Myocardial Imaging
US Patent:
5070877, Dec 10, 1991
Filed:
Mar 29, 1989
Appl. No.:
7/330156
Inventors:
Syed M. Mohiuddin - Omaha NE
Daniel E. Hilleman - Omaha NE
Daniel E. Hilleman - Omaha NE
Assignee:
MeDco Research, Inc. - Los Angeles CA
International Classification:
A61B 600
US Classification:
1286534
Abstract:
The parenteral use of adenosine, functional adenosine receptor agonists which include 1-methyl-2-phenylethyladenosine, 5-ethyl carboxamide adenosine, cyclopentyl adenosine and 2-chloro adenosine; metabolic precursors or by-products of adenosine which include adenine and inosine; and phosphorylated derivatives of adenosine including adenosine monophosphate, adenosine diphosphate and adenosine triphosphate in conjunction with various invasive and noninvasive diagnostic techniques to detect the presence or assess the severity of vascular disease is a novel application (indication) for these compounds and forms the basis of this patent application.